Insulin degludec/Liraglutide

德谷胰岛素/利拉鲁肽

Report date: 2026/05/20 20:02:01

Base Information

Drug NameInsulin degludec/Liraglutide
Drug Alias Nameinsulinum degludecum/liraglutidum地谷胰岛素/利拉鲁肽地谷胰岛素/利拉糖肽GLP-1 and basal insulin combinationinsulina degludec/liraglutida +[14] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists
TargetsGlucagon-like peptide 1 receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2014/09/18
Country/TerritoryCzechiaBulgariaCanada +[32] 
CombinationsYes Insulin degludecLiraglutide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesBiogenomicsNovo Nordisk A/S
Inactive CompaniesZhuhai Federation Biomedicine Co LtdLianbang Biotechnology (Zhuhai Hengqin) Co LtdNovo Nordisk (China)Pharmaceuticals Co Ltd +[5] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeA10AE56
Related LinksN/A